The Regulator

47: that is how many times Food and Drug Administration (FDA) inspectors documented microbial contamination at the German plant now driving a nationwide shortage of a chemotherapy drug that treats bone, soft tissue, and lymphoma cancers, many of them in children. The FDA issued a warning letter dated March 3, 2026 to Simtra Deutschland GmbH, formerly Baxter Oncology GmbH, at its Halle, Germany manufacturing site, after an unannounced inspection found 47 microbial recoveries in the plant’s highest cleanliness production lines over 27 months and a known design flaw the company never fixed, calling the drugs made there “adulterated.” Production of ifosfamide, sold under the brand Ifex and marketed generically, halted this spring, and the FDA’s own drug shortage database lists 1 gram and 3 gram vials as unavailable, with alternate makers Fresenius Kabi and Hikma rationing supply through allocation and unable to meet full demand; the FDA has authorized emergency imports of ifosfamide from overseas manufacturers that do not normally sell in the United States, and reporting this week found the shortage is expected to persist until at least October 2026. Louisiana pediatric oncologist Dr. Pinki Prasad said the shortage now forces doctors to weigh, before starting a cancer therapy cycle, whether the next dose will even be available two weeks later. Confidence: Medium-High. This run reviewed the FDA’s own warning letter and drug shortage database directly; patient and physician accounts come from a Spotlight on America investigation published August 31, 2026. Sources: Simtra Deutschland GmbH warning letter, U.S. Food and Drug Administration, Drug Shortages Database, U.S. Food and Drug Administration, Cancer drug shortages threaten lives as efforts to prevent them hit regulatory red tape, WJLA.

23: that is how many states just sued the Trump administration over new strings attached to Title X family planning grants, arguing the conditions illegally punish clinics that serve transgender patients or decline to steer women toward marriage and childbirth. New York Attorney General Letitia James, co-leading with Maryland and Massachusetts, filed suit August 27, 2026 in the U.S. District Court for the District of Maryland, arguing the Department of Health and Human Services (HHS) added conditions this summer requiring Title X recipients to eliminate diversity and inclusion practices, exclude transgender people from services, discourage contraception in favor of natural family planning, counsel patients toward marriage and parenthood, and align with unrelated priorities like “ending crime and disorder on America’s streets,” all without the notice and public comment federal law requires. New York alone receives roughly $11.1 million a year in Title X funding, supporting 165 health centers that serve more than 250,000 patients, and the states say noncompliant clinics could face staff reductions and contract cuts starting April 1, 2027, a deadline the coalition is asking the court to block. Confidence: High. This run reviewed the New York Attorney General’s press release and the filed complaint directly. Sources: Attorney General James Leads Lawsuit to Protect Title X Family Planning Services, New York Attorney General, State of New York et al. v. U.S. Department of Health and Human Services et al., complaint.

$82 million: that is how much the Centers for Medicare and Medicaid Services (CMS) says it would save every year under new fraud rules buried inside a routine home health payment update, and the comment period on them just closed. The proposed rule (CMS-1844-P), which sets calendar year 2027 payment rates for home health agencies, also proposes to let CMS revoke or deny Medicare enrollment for any provider or supplier operating in a designated high-fraud geographic area, for misdemeanor convictions involving sexual assault or financial misconduct within the past 10 years, and for noncompliance tied to ownership changes, while making every Medicare enrollment revocation retroactive to the date of noncompliance so CMS can claw back payments already made; the enrollment provisions would apply to all Medicare provider and supplier types, not just home health agencies, and the public comment window closed August 31, 2026. Confidence: Medium. CMS’s own newsroom page returned an access error to direct fetch this run; this account relies on CMS’s press release and fact sheet as summarized by trade press and law firm trackers. Sources: CMS Proposes Updates to Strengthen Medicare Program Integrity, Combat Fraud, and Expand Access to Home Health Care, Centers for Medicare and Medicaid Services, CMS mulls tougher Medicare enrollment rules to combat fraud as part of 2027 home health payment rule, Fierce Healthcare.

$7.5 million: that is what a Dallas-Fort Worth medical clinic will pay after billing the government for doctor visits that never happened, charging patients for an office exam every time they got a free COVID-19 nasal swab. The U.S. Attorney’s Office for the Northern District of Texas announced August 26, 2026 that Aymancare PLLC agreed to pay $7.5 million to resolve allegations that its pop-up COVID-19 testing sites billed separate evaluation and management visit codes on top of testing codes, even though the encounters involved only a technician administering a nasal swab and no clinician ever saw the patient; the claims were paid through the Health Resources and Services Administration’s COVID-19 Uninsured Program, which used federal funds to cover testing, treatment, and vaccine costs for people without insurance during the pandemic. Confidence: Medium. Justice.gov’s own press release returned an access error to direct fetch this run, a recurring pattern with the Department of Justice; this account relies on the HHS Office of Inspector General’s enforcement log and trade press. Sources: Enforcement Actions, HHS Office of Inspector General, Feds: Dallas Clinic Aymancare to Pay $7.5M for Allegedly COVID-19 Testing Fraud, CJ Notebook.

$7,000: that is what a benchmark health plan would cost a single Rhode Islander every year under one insurer’s proposed 2027 rate increase, and the state’s Attorney General is now asking regulators to reject it. Attorney General Peter Neronha filed formal objections August 25, 2026 with Rhode Island’s Office of the Health Insurance Commissioner (OHIC) against 2027 individual market rate requests from Neighborhood Health Plan of Rhode Island, seeking a 22 percent increase, and Blue Cross Blue Shield of Rhode Island, seeking 9.8 percent, together affecting more than 50,000 Rhode Islanders; Neronha’s expert testimony argued Neighborhood Health Plan failed to adequately fund its primary care spending obligations, while Blue Cross Blue Shield generated $54 million in additional revenue last year and is on pace for a $50 million profit in 2026 without showing how it would improve affordability. The objections come as expiring federal enhanced premium tax credits already push individual market costs higher nationwide, though Rhode Island’s own Market Place Affordability Program offers partial relief to lower income enrollees; OHIC will weigh the Attorney General’s filing before issuing final 2027 rates. Confidence: High. This run reviewed the Rhode Island Attorney General’s press release directly. Sources: Attorney General Neronha objects to proposed increases to 2027 statewide healthcare insurance rates, Rhode Island Attorney General’s Office.